Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment

BACKGROUND: Hepatitis B surface antigen (HBsAg) loss/seroconversion is considered to be the ideal endpoint of antiviral therapy and the ultimate treatment goal in chronic hepatitis B (CHB). This study aimed to assess the patterns of HBsAg kinetics in CHB patients who achieved HBsAg loss during the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ming-Hui, Zhang, Lu, Qu, Xiao-Jing, Lu, Yao, Shen, Ge, Wu, Shu-Ling, Chang, Min, Liu, Ru-Yu, Hu, Lei-Ping, Li, Zhen-Zhen, Hua, Wen-Hao, Song, Shu-Jing, Xie, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339929/
https://www.ncbi.nlm.nih.gov/pubmed/28229987
http://dx.doi.org/10.4103/0366-6999.200554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339929/
https://www.ncbi.nlm.nih.gov/pubmed/28229987
http://dx.doi.org/10.4103/0366-6999.200554

Ejemplares similares